Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.

Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group.

Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14.

2.

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group.

Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26.

PMID:
29395273
3.

Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.

Setnik B, Roland CL, Pixton GC, Sommerville KW.

Postgrad Med. 2017 Jan;129(1):5-11. doi: 10.1080/00325481.2017.1245585. Epub 2016 Oct 26.

PMID:
27782769
4.

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.

Setnik B, Bass A, Bramson C, Levy-Cooperman N, Malhotra B, Matschke K, Geoffroy P, Sommerville KW, Wolfram G.

Pain Med. 2017 Jun 1;18(6):1077-1088. doi: 10.1093/pm/pnw178.

PMID:
27550954
5.

Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.

Backonja M, Webster LR, Setnik B, Bass A, Sommerville KW, Matschke K, Malhotra BK, Wolfram G.

Am J Drug Alcohol Abuse. 2016 Sep;42(5):539-549. Epub 2016 May 21.

PMID:
27211522
6.

A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain.

Setnik B, Roland CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V.

J Pain Res. 2015 Jul 9;8:361-73. doi: 10.2147/JPR.S82396. eCollection 2015.

8.

Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.

Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P.

J Clin Pharmacol. 2015 Dec;55(12):1351-61. doi: 10.1002/jcph.552. Epub 2015 Jul 2.

PMID:
26011742
9.

A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.

Rauck RL, Hale ME, Bass A, Bramson C, Pixton G, Wilson JG, Setnik B, Meisner P, Sommerville KW, Malhotra BK, Wolfram G.

Pain. 2015 Sep;156(9):1660-9. doi: 10.1097/j.pain.0000000000000230.

PMID:
25993547
10.

A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.

Arora S, Setnik B, Michael D, Hudson JD, Clemmer R, Meisner P, Pixton GC, Goli V, Sommerville KW.

J Opioid Manag. 2014 Nov-Dec;10(6):423-36. doi: 10.5055/jom.2014.0239.

PMID:
25531960
11.

Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures.

Rogin J, Wheless J, Abou-Khalil B, Wolter KD, Pixton GC, Sherman NA, Shukla RB, Roland CL, Sommerville KW.

Epilepsia. 2014 Sep;55(9):1444-51. doi: 10.1111/epi.12685. Epub 2014 Jun 25.

12.

A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures.

Abou-Khalil B, Wheless J, Rogin J, Wolter KD, Pixton GC, Shukla RB, Sherman NA, Sommerville K, Goli V, Roland CL.

Epilepsia. 2013 Nov;54(11):1968-76. doi: 10.1111/epi.12373. Epub 2013 Sep 20.

14.
15.

Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.

Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E.

J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131.

PMID:
23247908
17.

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice AS, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D.

Pain. 2012 Jun;153(6):1148-58. doi: 10.1016/j.pain.2012.03.003. Epub 2012 Apr 9.

PMID:
22494920
18.

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide.

Goli V, Webster LR, Lamson MJ, Cleveland JM, Sommerville KW, Carter E.

Harm Reduct J. 2012 Mar 15;9:13. doi: 10.1186/1477-7517-9-13.

19.
20.

Hydraulic conductance of Acacia phyllodes (foliage) is driven by primary nerve (vein) conductance and density.

Sommerville KE, Sack L, Ball MC.

Plant Cell Environ. 2012 Jan;35(1):158-68. doi: 10.1111/j.1365-3040.2011.02425.x. Epub 2011 Oct 18.

21.

Efficacy and safety of lacosamide in painful diabetic neuropathy.

Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, Sommerville K; Lacosamide SP743 Study Group.

Diabetes Care. 2010 Apr;33(4):839-41. doi: 10.2337/dc09-1578. Epub 2010 Jan 12.

22.

The influence of environment and life-history traits on the distribution of genes and individuals: a comparative study of 11 rainforest trees.

Rossetto M, Crayn D, Ford A, Mellick R, Sommerville K.

Mol Ecol. 2009 Apr;18(7):1422-38. doi: 10.1111/j.1365-294X.2009.04111.x.

PMID:
19284473
23.

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K; Rotigotine SP 709 Study Group.

Sleep Med. 2008 Mar;9(3):228-39. Epub 2007 Jun 5.

PMID:
17553743
24.
25.

Bioequivalence in development of antiepileptic drugs.

Sommerville KW.

Epilepsy Res. 2006 Jan;68(1):82-5. Review.

PMID:
16377144
26.

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.

Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B.

Clin Neuropharmacol. 2005 May-Jun;28(3):106-10.

PMID:
15965307
27.
28.

Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.

Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM; Depakote Comparator Study Group.

J Clin Psychiatry. 2003 Mar;64(3):288-94.

PMID:
12716270
29.

Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.

Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB.

Neuropsychopharmacology. 2003 Jun;28(6):1186-97. Epub 2003 Apr 2.

31.

Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy.

Ramsay RE, Cantrell D, Collins SD, Walch JK, Naritoku DK, Cloyd JC, Sommerville K.

Epilepsy Res. 2003 Jan;52(3):189-201.

PMID:
12536052
32.

A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.

Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW.

J Clin Psychiatry. 2002 Dec;63(12):1148-55.

PMID:
12523875
33.

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.

Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW.

Neuropsychopharmacology. 2003 Jan;28(1):182-92.

34.

Acute pancreatitis coincident with valproate use: a critical review.

Pellock JM, Wilder BJ, Deaton R, Sommerville KW.

Epilepsia. 2002 Nov;43(11):1421-4.

35.
36.

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.

Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K; Depakote ER Migraine Study Group.

Neurology. 2002 Jun 11;58(11):1652-9.

PMID:
12058094
37.

Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment.

Sackellares JC, Krauss G, Sommerville KW, Deaton R.

Epilepsia. 2002 Apr;43(4):394-8.

38.
39.

The short-term impact of adjunctive tiagabine on health-related quality of life.

Cramer J, Ryan J, Chang J, Sommerville K; M92-825 Study Group.

Epilepsia. 2001;42 Suppl 3:70-5.

40.

Characterisation of dissolved combined amino acids in marine waters.

Sommerville K, Preston T.

Rapid Commun Mass Spectrom. 2001;15(15):1287-90.

PMID:
11466786
41.

Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons.

Shinnar S, Berg AT, Treiman DM, Hauser WA, Hesdorffer DC, Sackellares JC, Leppik I, Sillanpaa M, Sommerville KW.

Epilepsia. 2001 Mar;42(3):372-9.

42.

Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.

Dodrill CB, Arnett JL, Deaton R, Lenz GT, Sommerville KW.

Epilepsy Res. 2000 Dec;42(2-3):123-32.

PMID:
11074185
43.

Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin.

Hogan RE, Bertrand ME, Deaton RL, Sommerville KW.

Epilepsy Res. 2000 Aug;41(1):23-8.

PMID:
10924865
44.

Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.

Gustavson LE, Cato A 3rd, Boellner SW, Cao GX, Qian JX, Guenther HJ, Sommerville KW.

Am J Ther. 1998 Jan;5(1):9-16.

PMID:
10099032
45.

Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.

Gustavson LE, Sommerville KW, Boellner SW, Witt GF, Guenther HJ, Granneman GR.

Am J Ther. 1998 Mar;5(2):73-9.

PMID:
10099041
46.

Safety of tiagabine: summary of 53 trials.

Leppik IE, Gram L, Deaton R, Sommerville KW.

Epilepsy Res. 1999 Feb;33(2-3):235-46.

PMID:
10094434
47.

Comparison of duplex imaging and arteriography in the evaluation of lower limb arteries.

Aly S, Sommerville K, Adiseshiah M, Raphael M, Coleridge Smith PD, Bishop CC.

Br J Surg. 1998 Aug;85(8):1099-102.

PMID:
9718005
48.

Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.

Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW.

Epilepsia. 1998 Aug;39(8):868-73.

49.

Prospective randomized trial of woven versus collagen-impregnated knitted prosthetic Dacron grafts in aortoiliac surgery.

Quarmby JW, Burnand KG, Lockhart SJ, Donald AE, Sommerville KM, Jamieson CW, Browse NL.

Br J Surg. 1998 Jun;85(6):775-7.

PMID:
9667705
50.

Effects of tiagabine monotherapy on abilities, adjustment, and mood.

Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW.

Epilepsia. 1998 Jan;39(1):33-42.

Supplemental Content

Loading ...
Support Center